Customer Care Tel: 0161 483 5884
Email: ukcustomer@alere.com
Website: www.alere.co.uk
Connecting withEmergency Medicine
Plasma NGAL is an early marker of AKI in adult critically ill patients
Plasma NGAL is an early marker of acute kidney injury (AKI) in adult critically ill patients: A prospective study.
Jean-Michel Constantin MD, PhD et al.1 Hôtel-Dieu Hospital, Clermont-Ferrand, France
Throughout the literature, one will find the incidence of AKI in ICU (Intensive Care Unit) patients to be very high (up to 67% in one large study).2 AKI alone has associated morbidity and mortality.3 Some of those patients will ultimately lose kidney function entirely and develop the need for renal replacement therapy (dialysis). When this occurs, mortality rates are extremely high, approaching 63%.4
Today, by the time AKI has been detected by standard clinical measures, such as serum creatinine, a substantial portion of renal function may already have been lost.5 Interventions may then not have much effect on the patient’s outcome.
To view the full summary and for a full list of references click on the download tab below
Study Purpose
To assess the ability of plasma neutrophil gelatinase-associated lipocalin (pNGAL) as measured with the Alere Triage® NGAL Test, to predict AKI in adult ICU patients.
To view the full summary and for a full list of references click on the download tab below